UY35946A - Composiciones que contienen (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profármacos, como ligandos para el receptor de nmda nr2b - Google Patents

Composiciones que contienen (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profármacos, como ligandos para el receptor de nmda nr2b

Info

Publication number
UY35946A
UY35946A UY0001035946A UY35946A UY35946A UY 35946 A UY35946 A UY 35946A UY 0001035946 A UY0001035946 A UY 0001035946A UY 35946 A UY35946 A UY 35946A UY 35946 A UY35946 A UY 35946A
Authority
UY
Uruguay
Prior art keywords
methylbencil
pirrolidin
ona
professionals
piperidin
Prior art date
Application number
UY0001035946A
Other languages
English (en)
Inventor
Lorin A Thompson Iii
John E Macor
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY35946A publication Critical patent/UY35946A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

En general, la descripción se refiere a compuestos de la Fórmula I, que incluyen sus sales, además de composiciones y métodos para usar los compuestos. Los compuestos son ligandos para el receptor de NMDA NR2B y se pueden usar para el tratamiento de distintos trastornos del sistema nervioso central.
UY0001035946A 2014-01-09 2015-01-09 Composiciones que contienen (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profármacos, como ligandos para el receptor de nmda nr2b UY35946A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461925405P 2014-01-09 2014-01-09

Publications (1)

Publication Number Publication Date
UY35946A true UY35946A (es) 2015-07-31

Family

ID=52444626

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035946A UY35946A (es) 2014-01-09 2015-01-09 Composiciones que contienen (r)-3-((3s,4s)-3-fluoro-4-(4-hidroxifenil)piperidin-1-il)-1-(4-metilbencil)pirrolidin-2-ona y sus profármacos, como ligandos para el receptor de nmda nr2b

Country Status (26)

Country Link
US (10) US9187506B2 (es)
EP (2) EP3092223B1 (es)
JP (1) JP6629738B2 (es)
KR (1) KR102331120B1 (es)
AR (1) AR102019A1 (es)
AU (1) AU2015204785A1 (es)
CA (1) CA2936338A1 (es)
CL (1) CL2016001744A1 (es)
CY (1) CY1122768T1 (es)
DK (1) DK3092223T3 (es)
EA (1) EA201691133A1 (es)
ES (1) ES2771825T3 (es)
HR (1) HRP20200161T1 (es)
HU (1) HUE048750T2 (es)
IL (1) IL246596A0 (es)
LT (1) LT3092223T (es)
MX (1) MX2016008715A (es)
PE (1) PE20160898A1 (es)
PL (1) PL3092223T3 (es)
PT (1) PT3092223T (es)
RS (1) RS59858B1 (es)
SG (1) SG11201605620QA (es)
SI (1) SI3092223T1 (es)
TW (1) TW201612169A (es)
UY (1) UY35946A (es)
WO (1) WO2015105929A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
AU2016340239A1 (en) * 2015-10-14 2018-05-31 Bristol-Myers Squibb Company Selective NR2B antagonists
EP3362441B1 (en) * 2015-10-14 2020-08-12 Bristol-Myers Squibb Company Selective nr2b antagonists
US12086719B2 (en) * 2019-10-11 2024-09-10 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476041B1 (en) * 1999-10-29 2002-11-05 Merck & Co., Inc. 1,4 substituted piperidinyl NMDA/NR2B antagonists
KR20020093950A (ko) 2000-04-26 2002-12-16 워너-램버트 캄파니 아형 선택적인 ｎｍｄａ 수용체 길항제로서의시클로헥실아민 유도체
WO2003035641A1 (fr) 2001-10-22 2003-05-01 Shionogi & Co., Ltd. Nouveau derive carbamoyl-pyrrolidone
CA2527093C (en) 2003-06-04 2009-10-20 Merck & Co., Inc. 3-fluoro-piperidines as nmda/nr2b antagonists
WO2005035523A1 (en) 2003-10-08 2005-04-21 Pfizer Japan Inc. Fused lactam compounds
EP1988077A4 (en) 2006-02-23 2009-09-02 Shionogi & Co NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
CN101815518B (zh) 2007-06-29 2013-01-09 埃莫里大学 用于神经保护的nmda受体拮抗剂
CA2705336A1 (en) * 2007-11-13 2009-05-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives as modulators of ion channels
US9187506B2 (en) * 2014-01-09 2015-11-17 Bristol-Myers Squibb Company (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

Also Published As

Publication number Publication date
DK3092223T3 (da) 2020-03-16
ES2771825T3 (es) 2020-07-07
CN105873915A (zh) 2016-08-17
LT3092223T (lt) 2020-02-25
WO2015105929A1 (en) 2015-07-16
US20170340653A1 (en) 2017-11-30
PL3092223T3 (pl) 2020-05-18
US20180250316A1 (en) 2018-09-06
SI3092223T1 (sl) 2020-02-28
PT3092223T (pt) 2020-02-19
IL246596A0 (en) 2016-08-31
US20190125770A1 (en) 2019-05-02
SG11201605620QA (en) 2016-08-30
US20150191496A1 (en) 2015-07-09
US20190314392A1 (en) 2019-10-17
KR102331120B1 (ko) 2021-11-24
US20180104265A1 (en) 2018-04-19
KR20160101194A (ko) 2016-08-24
US9187506B2 (en) 2015-11-17
US20170216325A1 (en) 2017-08-03
CY1122768T1 (el) 2021-05-05
EP3092223B1 (en) 2019-12-11
PE20160898A1 (es) 2016-09-10
AU2015204785A1 (en) 2016-08-25
MX2016008715A (es) 2016-09-06
RS59858B1 (sr) 2020-02-28
HRP20200161T1 (hr) 2020-05-01
EP3677578A1 (en) 2020-07-08
EA201691133A1 (ru) 2017-05-31
CA2936338A1 (en) 2015-07-16
TW201612169A (en) 2016-04-01
CL2016001744A1 (es) 2017-03-17
HUE048750T2 (hu) 2020-08-28
JP6629738B2 (ja) 2020-01-15
US20200297742A1 (en) 2020-09-24
US20160030456A1 (en) 2016-02-04
JP2017503804A (ja) 2017-02-02
EP3092223A1 (en) 2016-11-16
US20170065573A1 (en) 2017-03-09
AR102019A1 (es) 2017-02-01

Similar Documents

Publication Publication Date Title
CL2019003015A1 (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2015002125A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
SV2018005794A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
CL2018003265A1 (es) Modulares del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
ECSP20018487A (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
CL2017001511A1 (es) Derivados de piperidina como inhibidores de hdac1/2.
CL2016002084A1 (es) Compuestos derivados de ciclopentano 1,2 substituidos como antagonistas del receptor de orexina.
NI201700129A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa.
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
UY36348A (es) Derivados de benzotiofenilo sustituidos como agonistas del gpr40 para el tratamiento de la diabetes tipo ii
DOP2016000312A (es) Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2
CO2018004573A2 (es) Derivados de fenilo como agonistas del receptor 2 de cannabinoides
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
CL2015003195A1 (es) Derivados de purina como agonistas del receptor cb2.
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
CY1122768T1 (el) (r)-3-((3s,4s)-3-φθορο-4-(4-υδροξυφαινυλ)πιπεριδιν-1-υλ)-1-(4-μεθυλβενζυλ)πυρρολιδιν-2-ονη και προφαρμακα αυτης για τη θεραπεια ψυχιατρικων διαταραχων